Lunai Bioworks Inc. Common Stock
Veridion Score
Composite trend over time
Why is LNAI moving today?
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for LNAI.
LNAI insider activity
Lunai Bioworks Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for LNAI.
LNAI contract awards, year to date.
Public federal awards linked to this ticker.
LNAI lobbying filings, year to date.
Registered lobbying filings matched to Lunai Bioworks Inc. Common Stock.